The Smiling Heretic
By Daniel S. Levine,
The Journal of Life Sciences
| 05. 16. 2008
[Quotes CGS's Marcy Darnovsky]
Reg Kelly has an infectious smile that seems to be part childlike wonder and part wise guy. The fun, though, is in listening to Kelly talk. His words come in enthusiastic bursts, coated in a Scottish accent that makes everything he says seem just a tad more colorful. And what he says conveys just enough distaste for authority to give him what amounts to, in the bureaucratic world of academia, a bad-boy edge.
But when it's suggested to the head of California's Institute for Quantitative Biosciences, or QB3, that his charm might be what makes him so effective at raising money, negotiating deals with corporate partners, and circumventing institutional barriers, he is quick to correct. "It's not charm," Kelly says. "What it is, is the belief that this is worth doing. It's the passion. We have a very clear vision, and people like that."
QB3 is one of four California Institutes for Science and Innovation established in 2000 by then-Governor Gray Davis. Headquartered at the Mission Bay campus of the University of California, San Francisco, QB3 extends across three University...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...